Concepedia

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

Xavier Pivot, Andreas Schneeweiß, Shailendra Verma, Christoph Thomssen, José Luís Passos‐Coelho, Giovanni Benedetti, Eva Ciruelos, Roger von Moos, Hong‐Tai Chang, Anja-Alexandra Duenne,

European Journal of Cancer · 2011 · 110 citations · 29 references

DOI

Concepts

References

29

Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

Laura F. Hutchins, Joseph M. Unger, John J. Crowley et al. · New England Journal of Medicine · 1999 · 2.2K citations

, , +13

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

, , +15

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

, , +17

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

George W. Sledge, Donna Neuberg, Patricia Bernardo et al. · Journal of Clinical Oncology · 2003 · 707 citations

, , +15

Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer

Sami Diab · JNCI Journal of the National Cancer Institute · 2000 · 680 citations · Full text

, , +16